Covid-19 vaccination among migrants in Rome, Italy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
10
07
2023
accepted:
24
11
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
Migrants may be susceptible to vaccine barriers and hesitancy. We evaluated the association between migrant status, as measured by the citizenship from a High Migratory Pressure Country (HMPC), and COVID-19 vaccination uptake in the resident population in Rome, Italy. We also investigated sex differences. We followed participants for vaccination against COVID-19 in 2021. We calculated crude- and adjusted-vaccination rates and Cox hazard ratios of vaccination for migrants compared to Italians. Among migrants from HMPCs, we estimated HRs for females compared to males, stratifying by geographical area of origin. Models were adjusted for age and deprivation index and stratified by infection history. In 2021, among 1,731,832 18-64-year-olds, migrants were 55% less likely to uptake at least one COVID-19 vaccine dose than their Italian counterpart. Past SARS-CoV-2 infection reduced the difference between migrants and Italians to 27%. Among migrants from HMPCs, we observed a slight excess of vaccination uptake among females compared to males. Focusing on geographical areas, we observed that only females from central-western Asia were 9% less likely to uptake vaccination than males. Health communication strategies oriented to migrants and considering their different languages, cultures, and health literacy should be adopted for prevention before emergencies.
Identifiants
pubmed: 38017018
doi: 10.1038/s41598-023-48273-4
pii: 10.1038/s41598-023-48273-4
pmc: PMC10684578
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20890Informations de copyright
© 2023. The Author(s).
Références
BMC Public Health. 2023 Feb 24;23(1):391
pubmed: 36829138
Hum Vaccin Immunother. 2018 Feb 1;14(2):478-488
pubmed: 29048987
Epidemiol Prev. 2020 Mar-Jun;44(2-3):162-170
pubmed: 32631016
Public Health. 2022 Oct;211:136-143
pubmed: 36113199
Eur J Public Health. 2021 Feb 1;31(1):37-44
pubmed: 33416859
J Migr Health. 2022;5:100086
pubmed: 35194589
Int J Health Plann Manage. 2018 Mar 30;:
pubmed: 29602177
Epidemiol Prev. 2022 Jul-Aug;46(4):49-58
pubmed: 35862560
Expert Rev Vaccines. 2022 Aug;21(8):1147-1157
pubmed: 35584901
Epidemiol Prev. 2022 Jul-Aug;46(4):33-40
pubmed: 35862558
Swiss Med Wkly. 2022 Apr 08;152:w30162
pubmed: 35429238
Epidemiol Prev. 2022 Jul-Aug;46(4):41-48
pubmed: 35862559
Lancet Infect Dis. 2022 Sep;22(9):e254-e266
pubmed: 35429463
J Migr Health. 2021;3:100041
pubmed: 33903857
Epidemiol Prev. 2022 Jul-Aug;46(4):1-88
pubmed: 35862564
Epidemiol Prev. 2022 Jul-Aug;46(4):59-69
pubmed: 35862561
Life (Basel). 2022 Jul 07;12(7):
pubmed: 35888096
SSM Qual Res Health. 2023 Jun;3:100210
pubmed: 36573229
Vaccine. 2019 Apr 10;37(16):2179-2187
pubmed: 30902479
Vaccines (Basel). 2022 Feb 25;10(3):
pubmed: 35334995
Front Public Health. 2022 Feb 09;10:817696
pubmed: 35223739
Epidemiol Prev. 2010 Jul-Aug;34(4):167-76
pubmed: 21224518
J Public Health (Oxf). 2023 Mar 14;45(1):e65-e74
pubmed: 34994801
Pathog Glob Health. 2017 Mar;111(2):59-68
pubmed: 28165878